

EUROPEAN JOURNAL OF NANOMEDICINE

EDITORS-IN-CHIEF

Patrick Hunziker, University Hospital Basel, Switzerland

Jan Mollenhauer, University of Southern Denmark, Odense, Denmark

SCIENTIFIC MANAGING EDITOR

Georgette B. Salieb-Beugelaar, University Hospital Basel, Switzerland

MANAGING EDITOR CLINAM

Beat Löffler, European Foundation for Clinical Nanomedicine, Basel, Switzerland

EDITORS

Christoph Alexiou, University Hospital Erlangen, Germany

Yechezkel Barenholz, The Hebrew University of Jerusalem, Israel

Kenneth Dawson, University College Dublin, Ireland

Andreas Jordan, MagForce Nanotechnologies AG, Berlin, Germany

Claus-Michael Lehr, Saarland University, Saarbrücken, Germany

Bert Müller, University of Basel, Switzerland

Giacinto Scoles, Princeton University, Princeton, New Jersey, USA

Patrick W. Serruys, Erasmus University Medical Center, Rotterdam, The Netherlands

Janos Szebeni, Semmelweis University, Budapest, Hungary

EDITORIAL ADVISOR

Lajos Balogh, AA Nanomedicine & Nanotechnology Consultants, Boston, Massachusetts, USA

DE GRUYTER

published in cooperation with CLINAM – European Foundation for Clinical Nanomedicine

The publisher, together with the authors and editors, has taken great pains to ensure that all information presented in this work (programs, applications, amounts, dosages, etc.) reflects the standard of knowledge at the time of publication. Despite careful manuscript preparation and proof correction, errors can nevertheless occur. Authors, editors and publisher disclaim all responsibility for any errors or omissions or liability for the results obtained from use of the information, or parts thereof, contained in this work.

The citation of registered names, trade names, trademarks, etc. in this work does not imply, even in the absence of a specific statement, that such names are exempt from laws and regulations protecting trademarks etc. and therefore free for general use.

ISSN 1662-5986 · e-ISSN 1662-596X

All information regarding notes for contributors, subscriptions, open access, back volumes and orders is available online at www.degruyter.com/view/j/ejnm

RESPONSIBLE EDITORS Prof. Dr. med. Patrick Hunziker, University Hospital Basel and European Foundation for Clinical Nanomedicine - CLINAM, Basel, CH, Email: hunziker@clinam.org

Prof. Dr. Jan Mollenhauer, Head Molecular Oncology and Director Lundbeckfonden Center of Excellence NanoCAN, IMM - Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark, Email: jmollenhauer@health.sdu.dk

Beat Löffler, CEO of the European Foundation for Clinical Nanomedicine - CLINAM, Basel, CH, Email: loeffler@clinam.org

SCIENTIFIC MANAGING EDITOR Dr. Ing. Georgette B. Salieb-Beugelaar, University Hospital Basel, CH, Email: beugelaar@swissnano.org

JOURNAL MANAGER Dr. Karin E. Lason, De Gruyter, Genthiner Straße 13, 10785 Berlin, Germany, Tel.: +49 (0)30 26005-276, Fax: +49 (0)30 26005-184, Email: eujnm.editorial@degruyter.com

RESPONSIBLE FOR ADVERTISEMENTS Panagiota Herbrand, De Gruyter, Rosenheimer Straße 143, 81671 München, Germany.

Tel.: +49 (0)89 769 02 – 394, Fax: +49 (0)89 769 02 – 350

Email: panagiota.herbrand@degruyter.com

© 2014 Walter de Gruyter GmbH, Berlin/Boston

TYPESETTING Compuscript Ltd., Shannon, Ireland

PRINTING Franz X. Stückle Druck und Verlag e.K., Ettenheim

Printed in Germany

COVER ILLUSTRATION Nanomedicine is a young and innovative field that offers interesting approaches for diagnostics and therapy in personalized medicine. Especially targeted nanoparticles like surface functionalized liposomes offer new possibilities as homing devices for various drugs or contrast agents. Targeted liposomes tested for cardiovascular imaging typically consist of a targeting sequence, primarily a protein or antibody, conjugated to a polymer grafted liposome, which is fused to a contrast agent appropriate to the particular imaging technique applied. To gain new insights towards early diagnosis and monitoring of atherosclerosis in individuals at risk well before fatal clinical endpoints occur, special attention is paid to disease related anti-inflammatory biomarkers as molecular targets. The cover image shows a targeted stealth liposome. To inform yourself more on this topic please see the contribution of Mangge, Almer, Opriessnig, and Prassl on *Anti-inflammatory mediators for molecular imaging of atherosclerosis* on pages 103–113 in this issue.

Copyright holder of the image: Ruth Prassl, Institut für Biophysik, Medizinische Universität Graz, Harrachgasse 21, 8010 Graz, Austria.



Contents

Guest Editorial and News

Didier Letourneur

Cardiovascular nanomedicine — 55

Beat Löffler

News from the European Foundation for Nanomedicine (CLINAM): The 2014 CLINAM SUMMIT — 57

Georgette B. Salieb-Beugelaar

What's up in nanomedicine for cardiovascular diseases? — 59

Review Articles

Iwona Cicha, Christoph D. Garlich and Christoph Alexiou
Cardiovascular therapy through nanotechnology – how far are we still from bedside? — 63

Mira Marcus-Kalish and Hamutal Meiri

The simultaneous systematic analysis approach for personalized management of cardiovascular diseases — 89

Gunter Almer, Peter Opriessnig, Ruth Prassl and Harald Mangge

Anti-inflammatory mediators for molecular imaging of atherosclerosis — 103

Perspectives

Didier Letourneur and Panagiotis N. Trohopoulos

Atherosclerotic disease and management challenges with nanomedicine: EU FP7 NMP funded “NanoAthero” and “CosmoPHOS-nano” large-scale projects — 115